Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M.

J Pharm Pharmacol. 2014 Jul;66(7):975-87. doi: 10.1111/jphp.12223. Epub 2014 Feb 17.

PMID:
24533859
2.

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.

Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, Miyoshi S, Tahara A, Kurosaki E, Li Q, Tomiyama H, Sasamata M, Shibasaki M, Uchiyama Y.

Eur J Pharmacol. 2014 Mar 15;727:66-74. doi: 10.1016/j.ejphar.2014.01.040. Epub 2014 Jan 30.

PMID:
24486393
3.

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M.

Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55. doi: 10.1016/j.ejphar.2013.05.014. Epub 2013 May 23.

PMID:
23707905
4.

In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats.

Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, Ueshima K, Sato S, Sasamata M.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):247-53. doi: 10.1007/s00210-012-0821-4. Epub 2012 Dec 14.

PMID:
23239087
5.

Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M.

J Pharmacol Sci. 2012;120(1):36-44. Epub 2012 Aug 23.

6.

Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.

Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Kobori M, Katou M, Tawara S, Kawabata S, Furuichi K.

Biochem Biophys Res Commun. 2012 Sep 7;425(4):711-6. doi: 10.1016/j.bbrc.2012.07.103. Epub 2012 Jul 27.

PMID:
22842455
7.

Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.

Kita A, Mitsuoka K, Kaneko N, Nakata M, Yamanaka K, Jitsuoka M, Miyoshi S, Noda A, Mori M, Nakahara T, Sasamata M.

J Pharmacol Exp Ther. 2012 Oct;343(1):178-83. doi: 10.1124/jpet.112.195925. Epub 2012 Jul 11.

PMID:
22787117
8.

[Pharmacological and clinical profile of mirabegron (Betanis(®)): a new therapeutic agent for overactive bladder].

Suzuki M, Ukai M, Sasamata M, Seki N.

Nihon Yakurigaku Zasshi. 2012 May;139(5):219-25. Review. Japanese. No abstract available.

PMID:
22687876
9.

Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.

Nakamura N, Yamauchi T, Hiramoto M, Yuri M, Naito M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Yokota H, Kawabata S, Furuichi K.

Mol Cell Proteomics. 2012 Jul;11(7):M111.013243. doi: 10.1074/mcp.M111.013243. Epub 2012 Mar 22.

10.

Effects of α1-adrenoceptor antagonists on phenylephrine-induced salivary secretion and intraurethral pressure elevation in anesthetized rats.

Yanai-Inamura H, Ohtake A, Noguchi Y, Hatanaka T, Suzuki M, Ueshima K, Sato S, Sasamata M.

Eur J Pharmacol. 2012 Mar 15;679(1-3):127-31. doi: 10.1016/j.ejphar.2012.01.019. Epub 2012 Feb 1.

PMID:
22314219
12.

Synergistic Effect by Co-Administration of Tamsulosin and Solifenacin on Bladder Activity in Rats.

Nishijima S, Sugaya K, Kadekawa K, Ashitomi K, Ohtake A, Sasamata M, Yamamoto H.

Low Urin Tract Symptoms. 2012 Jan;4(1):3-8. doi: 10.1111/j.1757-5672.2011.00107.x. Epub 2011 Oct 10.

PMID:
26676451
13.

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385(4):423-36. doi: 10.1007/s00210-011-0713-z. Epub 2011 Dec 3.

PMID:
22139434
14.

Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention/emptying induced bladder overactivity.

Okutsu H, Matsumoto S, Ohtake A, Suzuki M, Sato S, Sasamata M, Uemura H.

J Urol. 2011 Dec;186(6):2470-7. doi: 10.1016/j.juro.2011.07.085. Epub 2011 Oct 21.

PMID:
22019173
15.

Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.

Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, Kaneko N, Sasamata M.

Clin Cancer Res. 2011 Aug 15;17(16):5423-31. doi: 10.1158/1078-0432.CCR-10-3410. Epub 2011 Jul 7.

16.

YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.

Yamanaka K, Nakata M, Kaneko N, Fushiki H, Kita A, Nakahara T, Koutoku H, Sasamata M.

Int J Oncol. 2011 Sep;39(3):569-75. doi: 10.3892/ijo.2011.1077. Epub 2011 Jun 14.

PMID:
21674125
17.

YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.

Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H, Sasamata M.

Anticancer Drugs. 2011 Jun;22(5):454-62. doi: 10.1097/CAD.0b013e328344ac68.

PMID:
21389848
18.

Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.

Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N, Sasamata M.

Leuk Res. 2011 Jun;35(6):787-92. doi: 10.1016/j.leukres.2010.11.016. Epub 2011 Jan 14.

PMID:
21237508
19.

Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M, Sasamata M.

Cancer Sci. 2011 Mar;102(3):614-21. doi: 10.1111/j.1349-7006.2010.01834.x. Epub 2011 Jan 12.

20.

Effect of tamsulosin on bladder microcirculation in a rat ischemia-reperfusion model, evaluated by pencil lens charge-coupled device microscopy system.

Mizuno H, Yamamoto T, Okutsu H, Ohtake A, Sasamata M, Matsukawa Y, Funahashi Y, Kato M, Hattori R, Gotoh M.

Urology. 2010 Nov;76(5):1266.e1-5. doi: 10.1016/j.urology.2010.06.039.

PMID:
21056274
21.

[Survivin supressant: a promising target for cancer therapy and pharmacological profiles of YM155].

Kita A, Nakahara T, Takeuchi M, Kinoyama I, Yamanaka K, Minematsu T, Mitsuoka K, Fushiki H, Miyoshi S, Sasamata M, Miyata K.

Nihon Yakurigaku Zasshi. 2010 Oct;136(4):198-203. Review. Japanese. No abstract available.

PMID:
20948154
22.

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.

Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, Kita A, Koutoku H, Sasamata M, Hatashita E, Yamada Y, Kuwata K, Fukuoka M, Nakagawa K.

Br J Cancer. 2010 Jun 29;103(1):36-42. doi: 10.1038/sj.bjc.6605713. Epub 2010 Jun 1.

24.

Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure.

Someya Y, Nakano R, Tahara A, Takasu T, Takeuchi A, Nagase I, Matsuyama-Yokono A, Hayakawa M, Sasamata M, Miyata K, Uchiyama Y.

Eur J Pharmacol. 2009 Nov 10;622(1-3):71-7. doi: 10.1016/j.ejphar.2009.09.024. Epub 2009 Sep 17.

PMID:
19766107
25.

Zolpidem increases bladder capacity and decreases urine excretion in rats.

Yokoyama O, Matsuta Y, Yanai-Inamura H, Watanabe M, Ohtake A, Suzuki M, Sasamata M.

Neurourol Urodyn. 2010 Apr;29(4):587-91. doi: 10.1002/nau.20797.

PMID:
19760758
26.

Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.

Tanaka M, Mori H, Shimizu K, Toshiyuki, Matsuoka, Yamamotoya H, Minamide T, Mori M, Nozaki K, Usui T, Shimokawa K, Suzuki H, Aoyama K, Kimoto A, Sasamata M, Miyata K.

Nihon Yakurigaku Zasshi. 2009 Sep;134(3):149-57. doi: 10.1254/fpj.134.149. Review. Japanese. No abstract available.

PMID:
19749488
27.

Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction.

Okutsu H, Matsumoto S, Hanai T, Noguchi Y, Fujiyasu N, Ohtake A, Suzuki M, Sato S, Sasamata M, Uemura H, Kurita T.

Urology. 2010 Jan;75(1):235-40. doi: 10.1016/j.urology.2009.05.045. Epub 2009 Aug 3.

PMID:
19647304
28.

The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors.

Seeman P, Tokita K, Matsumoto M, Matsuo A, Sasamata M, Miyata K.

Synapse. 2009 Oct;63(10):930-4. doi: 10.1002/syn.20663.

PMID:
19588469
29.

Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.

Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S.

Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13.

PMID:
19446545
30.

[Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].

Hirata T, Funatsu T, Keto Y, Akuzawa S, Akiho H, Nishida A, Sasamata M, Miyata K.

Nihon Yakurigaku Zasshi. 2009 May;133(5):281-91. Review. Japanese. No abstract available.

PMID:
19443966
32.

Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.

Noguchi M, Kimoto A, Sasamata M, Miyata K.

J Bone Miner Metab. 2008;26(5):461-8. doi: 10.1007/s00774-008-0855-3. Epub 2008 Aug 30.

PMID:
18758904
33.

Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain models.

Kakimoto S, Nagakura Y, Tamura S, Watabiki T, Shibasaki K, Tanaka S, Mori M, Sasamata M, Okada M.

Eur J Pharmacol. 2008 Jul 28;589(1-3):98-101. doi: 10.1016/j.ejphar.2008.05.011. Epub 2008 May 20.

PMID:
18565509
34.

Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.

Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, Sasamata M, Miyata K.

Eur J Pharmacol. 2008 Jun 10;587(1-3):281-4. doi: 10.1016/j.ejphar.2008.03.040. Epub 2008 Mar 30.

PMID:
18456254
36.

YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.

Shindoh N, Mori M, Terada Y, Oda K, Amino N, Kita A, Taniguchi M, Sohda KY, Nagai K, Sowa Y, Masuoka Y, Orita M, Sasamata M, Matsushime H, Furuichi K, Sakai T.

Int J Oncol. 2008 Mar;32(3):545-55.

PMID:
18292931
37.

[Pre-clinical and clinical profiles of celecoxib, a new specific cyclooxygenase-2 inhibitor].

Kimoto A, Hanaoka A, Sasamata M, Miyata K.

Nihon Yakurigaku Zasshi. 2008 Feb;131(2):127-36. Review. Japanese. No abstract available.

PMID:
18277013
38.

Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer.

Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, Sasamata M, Miyata K.

Neurogastroenterol Motil. 2008 May;20(5):557-65. doi: 10.1111/j.1365-2982.2007.01069.x. Epub 2008 Jan 21.

PMID:
18221252
39.
40.

In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract.

Ukai M, Yuyama H, Fujimori A, Koakutsu A, Sanagi M, Ohtake A, Sato S, Sudoh K, Sasamata M, Miyata K.

Eur J Pharmacol. 2008 Feb 12;580(3):394-400. Epub 2007 Nov 23.

PMID:
18078923
41.
42.

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M, Sasamata M.

Cancer Res. 2007 Sep 1;67(17):8014-21. Erratum in: Cancer Res. 2012 Aug 1;72(15):3886. Mori, Masamichi [added]; Amino, Nobuaki [added]; Hatakeyama, Shinji [added];Minematsu, Tsuyoshi [removed]; Shirasuna, Kenna[removed].

43.

Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.

Funatsu T, Takeuchi A, Hirata T, Keto Y, Akuzawa S, Sasamata M.

Eur J Pharmacol. 2007 Nov 14;573(1-3):190-5. Epub 2007 Jul 3.

PMID:
17658508
44.

Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.

Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M.

J Pharmacol Sci. 2007 Jul;104(3):263-73.

45.

Relationship between the functional effect of tamsulosin and its concentration in lower urinary tract tissues in dogs.

Sato S, Ohtake A, Hatanaka T, Suzuki M, Matsushima H, Sasamata M, Miyata K.

Biol Pharm Bull. 2007 Mar;30(3):481-6.

46.

Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.

Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M.

Inflammopharmacology. 2007 Feb;15(1):5-9. Review.

PMID:
17323187
47.

Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.

Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O.

J Pharmacol Exp Ther. 2007 May;321(2):642-7. Epub 2007 Feb 9.

PMID:
17293563
48.

Vasopressin receptor antagonists: potential indications and clinical results.

Arai Y, Fujimori A, Sudoh K, Sasamata M.

Curr Opin Pharmacol. 2007 Apr;7(2):124-9. Epub 2007 Feb 9. Review.

PMID:
17292670
49.

Urodynamics and bladder muscarinic receptors in rats with cerebral infarction and bladder outlet obstruction.

Maruyama S, Kurosawa S, Takagi Y, Oki T, Noguchi Y, Ukai M, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Yamada S.

Neurosci Lett. 2007 Feb 27;414(1):80-4. Epub 2007 Jan 8.

PMID:
17267123
50.

Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test.

Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M.

Eur J Pharmacol. 2007 Feb 28;557(2-3):154-8. Epub 2006 Dec 1.

PMID:
17207478

Supplemental Content

Loading ...
Support Center